Yellow fever

A decade of reemergence

Susan E. Robertson, Barbara P. Hull, Oyewale Tomori, Okwo Bele, James LeDuc, Karin Esteves

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Since the 1980s, yellow fever has reemerged across Africa and in South America. The total of 18 735 yellow fever cases and 4522 deaths reported from 1987 to 1991 represents the greatest amount of yellow fever activity reported to the World Health Organization (WHO) for any 5-year period since 1948. There is an excellent vaccine against yellow fever. At present, a high proportion of travelers to at-risk areas are reported to be immunized, reflecting widespread knowledge about the International Health Regulations. In South America, yellow fever remains an occupational hazard for forest workers, who should be immunized. However, Aedes aegypti mosquitoes are now present in urban areas in the Americas (including southern parts of the United States), and there is concern that yellow fever could erupt in explosive outbreaks. In Africa, a large proportion of cases have occurred in children. The WHO, the United Nations Children's Fund (UNICEF), and the World Bank have recommended that 33 African countries at risk for yellow fever add the vaccine to the routine Expanded Programme on Immunization; studies show that this would be highly cost-effective. To date, financing yellow fever vaccine has been a major problem for these countries, which are among the poorest in the world. For this reason, WHO has launched an appeal to raise $70 million for yellow fever control in Africa.

Original languageEnglish (US)
Pages (from-to)1157-1162
Number of pages6
JournalJournal of the American Medical Association
Volume276
Issue number14
DOIs
StatePublished - Oct 9 1996
Externally publishedYes

Fingerprint

Yellow Fever
Yellow Fever Vaccine
South America
United Nations
Immunization Programs
Aedes
Culicidae
Disease Outbreaks
Costs and Cost Analysis
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Robertson, S. E., Hull, B. P., Tomori, O., Bele, O., LeDuc, J., & Esteves, K. (1996). Yellow fever: A decade of reemergence. Journal of the American Medical Association, 276(14), 1157-1162. https://doi.org/10.1001/jama.276.14.1157

Yellow fever : A decade of reemergence. / Robertson, Susan E.; Hull, Barbara P.; Tomori, Oyewale; Bele, Okwo; LeDuc, James; Esteves, Karin.

In: Journal of the American Medical Association, Vol. 276, No. 14, 09.10.1996, p. 1157-1162.

Research output: Contribution to journalArticle

Robertson, SE, Hull, BP, Tomori, O, Bele, O, LeDuc, J & Esteves, K 1996, 'Yellow fever: A decade of reemergence', Journal of the American Medical Association, vol. 276, no. 14, pp. 1157-1162. https://doi.org/10.1001/jama.276.14.1157
Robertson SE, Hull BP, Tomori O, Bele O, LeDuc J, Esteves K. Yellow fever: A decade of reemergence. Journal of the American Medical Association. 1996 Oct 9;276(14):1157-1162. https://doi.org/10.1001/jama.276.14.1157
Robertson, Susan E. ; Hull, Barbara P. ; Tomori, Oyewale ; Bele, Okwo ; LeDuc, James ; Esteves, Karin. / Yellow fever : A decade of reemergence. In: Journal of the American Medical Association. 1996 ; Vol. 276, No. 14. pp. 1157-1162.
@article{8b5fc428148d4d8b9ffdef71d97f51d1,
title = "Yellow fever: A decade of reemergence",
abstract = "Since the 1980s, yellow fever has reemerged across Africa and in South America. The total of 18 735 yellow fever cases and 4522 deaths reported from 1987 to 1991 represents the greatest amount of yellow fever activity reported to the World Health Organization (WHO) for any 5-year period since 1948. There is an excellent vaccine against yellow fever. At present, a high proportion of travelers to at-risk areas are reported to be immunized, reflecting widespread knowledge about the International Health Regulations. In South America, yellow fever remains an occupational hazard for forest workers, who should be immunized. However, Aedes aegypti mosquitoes are now present in urban areas in the Americas (including southern parts of the United States), and there is concern that yellow fever could erupt in explosive outbreaks. In Africa, a large proportion of cases have occurred in children. The WHO, the United Nations Children's Fund (UNICEF), and the World Bank have recommended that 33 African countries at risk for yellow fever add the vaccine to the routine Expanded Programme on Immunization; studies show that this would be highly cost-effective. To date, financing yellow fever vaccine has been a major problem for these countries, which are among the poorest in the world. For this reason, WHO has launched an appeal to raise $70 million for yellow fever control in Africa.",
author = "Robertson, {Susan E.} and Hull, {Barbara P.} and Oyewale Tomori and Okwo Bele and James LeDuc and Karin Esteves",
year = "1996",
month = "10",
day = "9",
doi = "10.1001/jama.276.14.1157",
language = "English (US)",
volume = "276",
pages = "1157--1162",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "14",

}

TY - JOUR

T1 - Yellow fever

T2 - A decade of reemergence

AU - Robertson, Susan E.

AU - Hull, Barbara P.

AU - Tomori, Oyewale

AU - Bele, Okwo

AU - LeDuc, James

AU - Esteves, Karin

PY - 1996/10/9

Y1 - 1996/10/9

N2 - Since the 1980s, yellow fever has reemerged across Africa and in South America. The total of 18 735 yellow fever cases and 4522 deaths reported from 1987 to 1991 represents the greatest amount of yellow fever activity reported to the World Health Organization (WHO) for any 5-year period since 1948. There is an excellent vaccine against yellow fever. At present, a high proportion of travelers to at-risk areas are reported to be immunized, reflecting widespread knowledge about the International Health Regulations. In South America, yellow fever remains an occupational hazard for forest workers, who should be immunized. However, Aedes aegypti mosquitoes are now present in urban areas in the Americas (including southern parts of the United States), and there is concern that yellow fever could erupt in explosive outbreaks. In Africa, a large proportion of cases have occurred in children. The WHO, the United Nations Children's Fund (UNICEF), and the World Bank have recommended that 33 African countries at risk for yellow fever add the vaccine to the routine Expanded Programme on Immunization; studies show that this would be highly cost-effective. To date, financing yellow fever vaccine has been a major problem for these countries, which are among the poorest in the world. For this reason, WHO has launched an appeal to raise $70 million for yellow fever control in Africa.

AB - Since the 1980s, yellow fever has reemerged across Africa and in South America. The total of 18 735 yellow fever cases and 4522 deaths reported from 1987 to 1991 represents the greatest amount of yellow fever activity reported to the World Health Organization (WHO) for any 5-year period since 1948. There is an excellent vaccine against yellow fever. At present, a high proportion of travelers to at-risk areas are reported to be immunized, reflecting widespread knowledge about the International Health Regulations. In South America, yellow fever remains an occupational hazard for forest workers, who should be immunized. However, Aedes aegypti mosquitoes are now present in urban areas in the Americas (including southern parts of the United States), and there is concern that yellow fever could erupt in explosive outbreaks. In Africa, a large proportion of cases have occurred in children. The WHO, the United Nations Children's Fund (UNICEF), and the World Bank have recommended that 33 African countries at risk for yellow fever add the vaccine to the routine Expanded Programme on Immunization; studies show that this would be highly cost-effective. To date, financing yellow fever vaccine has been a major problem for these countries, which are among the poorest in the world. For this reason, WHO has launched an appeal to raise $70 million for yellow fever control in Africa.

UR - http://www.scopus.com/inward/record.url?scp=0029758956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029758956&partnerID=8YFLogxK

U2 - 10.1001/jama.276.14.1157

DO - 10.1001/jama.276.14.1157

M3 - Article

VL - 276

SP - 1157

EP - 1162

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -